Intraday Performance and Price Movement
On 27 Mar 2026, Astrazeneca Pharma India Ltd’s shares fell sharply, marking a reversal after two consecutive days of gains. The stock’s intraday low of Rs 7,825 represented a 7.02% drop, significantly underperforming the Pharmaceuticals & Biotechnology sector by 5.99%. This decline was notably steeper than the Sensex’s fall of 2.25% on the same day, highlighting the stock’s relative weakness in a broadly negative market environment.
The stock’s price slipped below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend across multiple timeframes. This technical positioning suggests sustained selling pressure and a lack of immediate support levels within the short to medium term.
Market Context and Broader Sentiment
The decline in Astrazeneca Pharma India Ltd’s share price occurred against a backdrop of a sharply falling Sensex, which dropped 1,300.57 points to close at 73,583.22, down 2.25%. The index opened 389.66 points lower and continued to weaken throughout the session, nearing its 52-week low of 71,425.01, just 2.93% away. The Sensex’s trading below its 50-day moving average, which itself is below the 200-day moving average, reflects a bearish market environment that has weighed on stocks across sectors.
This broader market weakness has compounded the pressure on Astrazeneca Pharma India Ltd, which is classified as a small-cap stock within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score currently stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold on 2 Jan 2026. This downgrade reflects a deterioration in the stock’s overall quality and outlook as assessed by MarketsMOJO’s proprietary metrics.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Comparative Performance Analysis
Examining Astrazeneca Pharma India Ltd’s recent performance relative to the Sensex reveals consistent underperformance. Over the past day, the stock declined 6.84%, compared to the Sensex’s 2.25% fall. The one-week performance shows a 5.59% drop versus the Sensex’s 1.27% decline, while the one-month and three-month figures stand at -11.34% and -12.00%, respectively, compared to the Sensex’s -9.48% and -13.47%.
Over longer horizons, the stock’s performance remains mixed. The one-year return is -7.66%, lagging the Sensex’s -5.18%. Year-to-date, Astrazeneca Pharma India Ltd has fallen 12.99%, slightly outperforming the Sensex’s 13.66% decline. However, the stock’s three-year, five-year, and ten-year returns remain robust at 134.85%, 155.51%, and 571.38%, respectively, substantially outperforming the Sensex’s corresponding returns of 27.63%, 50.14%, and 190.41%.
Technical Indicators and Trend Assessment
Technical analysis of Astrazeneca Pharma India Ltd reveals predominantly bearish signals. The daily moving averages are all trending lower, reinforcing the downward momentum. The weekly MACD indicator is bearish, while the monthly MACD is mildly bearish, indicating weakening momentum over both intermediate and longer terms.
Other technical metrics such as the KST (Know Sure Thing) indicator show bearish trends on a weekly basis and mild bearishness monthly. Bollinger Bands suggest mild bearishness weekly but a mildly bullish stance monthly, reflecting some volatility and potential for short-term price fluctuations.
The Dow Theory assessment is mildly bearish on both weekly and monthly timeframes, while the On-Balance Volume (OBV) indicator also signals mild bearishness, suggesting that volume trends are not supporting price advances.
Considering Astrazeneca Pharma India Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Immediate Pressures and Market Sentiment
The sharp decline in Astrazeneca Pharma India Ltd’s share price reflects immediate selling pressure amid a broadly negative market mood. The stock’s fall below all major moving averages indicates a lack of short-term buying interest and suggests that traders are responding to the overall bearish environment affecting the Pharmaceuticals & Biotechnology sector and small-cap stocks in particular.
Market sentiment remains cautious as the Sensex approaches its 52-week low, with technical indicators signalling a continuation of the downtrend. This environment has contributed to the stock’s underperformance relative to both its sector and the broader market.
While Astrazeneca Pharma India Ltd’s longer-term performance remains strong, the current technical and market conditions have exerted downward pressure on the stock price, resulting in the intraday low observed on 27 Mar 2026.
Summary
In summary, Astrazeneca Pharma India Ltd’s intraday low of Rs 7,825 on 27 Mar 2026 was driven by a combination of sector underperformance, negative market sentiment, and bearish technical indicators. The stock’s decline of 7.02% on the day significantly outpaced the Sensex’s 2.25% fall, reflecting heightened selling pressure. Trading below all key moving averages and accompanied by bearish momentum indicators, the stock faces immediate challenges in regaining upward momentum amid a cautious market backdrop.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
